Which has stronger valuation and earnings, MED or LW?

Lamb Weston has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Lamb Weston, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medifast $385.79M 0.34 -$18.67M -$2.33 N/A Lamb Weston $6.61B 0.89 $290M $2.08 20.55

Is MED or LW more profitable?

Lamb Weston has a net margin of 4.39% compared to Medifast's net margin of -8.08%. Lamb Weston's return on equity of 23.33% beat Medifast's return on equity. Company Net Margins Return on Equity Return on Assets Medifast -8.08% -6.69% -5.25% Lamb Weston 4.39% 23.33% 5.72%

Does the media refer more to MED or LW?

In the previous week, Lamb Weston had 6 more articles in the media than Medifast. MarketBeat recorded 13 mentions for Lamb Weston and 7 mentions for Medifast. Lamb Weston's average media sentiment score of 0.23 beat Medifast's score of 0.21 indicating that Lamb Weston is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medifast 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lamb Weston 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, NOMD or MED?

Nomad Foods has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Nomad Foods, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nomad Foods $3.43B 0.43 $154.66M $1.02 10.40 Medifast $385.79M 0.34 -$18.67M -$2.33 N/A

Is NOMD or MED more profitable?

Nomad Foods has a net margin of 4.20% compared to Medifast's net margin of -8.08%. Nomad Foods' return on equity of 8.88% beat Medifast's return on equity. Company Net Margins Return on Equity Return on Assets Nomad Foods 4.20% 8.88% 3.53% Medifast -8.08% -6.69% -5.25%

Does the media prefer NOMD or MED?

In the previous week, Medifast had 6 more articles in the media than Nomad Foods. MarketBeat recorded 7 mentions for Medifast and 1 mentions for Nomad Foods. Nomad Foods' average media sentiment score of 0.67 beat Medifast's score of 0.21 indicating that Nomad Foods is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nomad Foods 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medifast 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PRE or MED?

In the previous week, Medifast had 6 more articles in the media than Prenetics Global. MarketBeat recorded 7 mentions for Medifast and 1 mentions for Prenetics Global. Medifast's average media sentiment score of 0.21 beat Prenetics Global's score of -0.09 indicating that Medifast is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prenetics Global 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Medifast 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend USNA or MED?

Medifast has a consensus target price of $12.00, suggesting a potential upside of 3.23%. Given Medifast's stronger consensus rating and higher probable upside, analysts clearly believe Medifast is more favorable than USANA Health Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score USANA Health Sciences 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Medifast 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media prefer USNA or MED?

In the previous week, Medifast had 6 more articles in the media than USANA Health Sciences. MarketBeat recorded 7 mentions for Medifast and 1 mentions for USANA Health Sciences. Medifast's average media sentiment score of 0.21 beat USANA Health Sciences' score of 0.00 indicating that Medifast is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment USANA Health Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Medifast 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer NAGE or MED?

In the previous week, Medifast had 1 more articles in the media than Niagen Bioscience. MarketBeat recorded 7 mentions for Medifast and 6 mentions for Niagen Bioscience. Medifast's average media sentiment score of 0.21 beat Niagen Bioscience's score of 0.00 indicating that Medifast is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Niagen Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Medifast 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Medifast (MED) Competitors

$11.64 +0.22 (+1.88%)

As of 11:45 AM Eastern

Compare

MED vs. LW, NOMD, PRE, USNA, and NAGE

Should you buy Medifast stock or one of its competitors? Medifast's main competitors and comparable companies include Lamb Weston (LW), Nomad Foods (NOMD), Prenetics Global (PRE), USANA Health Sciences (USNA), and Niagen Bioscience (NAGE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "consumer staples" sector.

How does Medifast compare to Lamb Weston?

Medifast (NYSE:MED) and Lamb Weston (NYSE:LW) are both consumer staples companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

Medifast has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Lamb Weston has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

Lamb Weston has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Lamb Weston, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medifast	$385.79M	0.34	-$18.67M	-$2.33	N/A
Lamb Weston	$6.61B	0.89	$290M	$2.08	20.55

95.5% of Medifast shares are owned by institutional investors. Comparatively, 89.6% of Lamb Weston shares are owned by institutional investors. 3.7% of Medifast shares are owned by insiders. Comparatively, 1.0% of Lamb Weston shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Lamb Weston had 6 more articles in the media than Medifast. MarketBeat recorded 13 mentions for Lamb Weston and 7 mentions for Medifast. Lamb Weston's average media sentiment score of 0.23 beat Medifast's score of 0.21 indicating that Lamb Weston is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medifast	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lamb Weston	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Medifast currently has a consensus target price of $12.00, suggesting a potential upside of 3.23%. Lamb Weston has a consensus target price of $52.73, suggesting a potential upside of 23.34%. Given Lamb Weston's stronger consensus rating and higher possible upside, analysts clearly believe Lamb Weston is more favorable than Medifast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medifast	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Lamb Weston	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23

Lamb Weston has a net margin of 4.39% compared to Medifast's net margin of -8.08%. Lamb Weston's return on equity of 23.33% beat Medifast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medifast	-8.08%	-6.69%	-5.25%
Lamb Weston	4.39%	23.33%	5.72%

Summary

Lamb Weston beats Medifast on 13 of the 16 factors compared between the two stocks.

How does Medifast compare to Nomad Foods?

Nomad Foods (NYSE:NOMD) and Medifast (NYSE:MED) are both small-cap consumer staples companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

In the previous week, Medifast had 6 more articles in the media than Nomad Foods. MarketBeat recorded 7 mentions for Medifast and 1 mentions for Nomad Foods. Nomad Foods' average media sentiment score of 0.67 beat Medifast's score of 0.21 indicating that Nomad Foods is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nomad Foods	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medifast	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nomad Foods has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Nomad Foods, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nomad Foods	$3.43B	0.43	$154.66M	$1.02	10.40
Medifast	$385.79M	0.34	-$18.67M	-$2.33	N/A

Nomad Foods has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market. Comparatively, Medifast has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

Nomad Foods has a net margin of 4.20% compared to Medifast's net margin of -8.08%. Nomad Foods' return on equity of 8.88% beat Medifast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nomad Foods	4.20%	8.88%	3.53%
Medifast	-8.08%	-6.69%	-5.25%

Nomad Foods presently has a consensus price target of $13.25, suggesting a potential upside of 24.88%. Medifast has a consensus price target of $12.00, suggesting a potential upside of 3.23%. Given Nomad Foods' stronger consensus rating and higher probable upside, analysts clearly believe Nomad Foods is more favorable than Medifast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nomad Foods	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Medifast	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

75.3% of Nomad Foods shares are held by institutional investors. Comparatively, 95.5% of Medifast shares are held by institutional investors. 17.3% of Nomad Foods shares are held by company insiders. Comparatively, 3.7% of Medifast shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Nomad Foods beats Medifast on 14 of the 16 factors compared between the two stocks.

How does Medifast compare to Prenetics Global?

Prenetics Global (NASDAQ:PRE) and Medifast (NYSE:MED) are both small-cap consumer staples companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Medifast has higher revenue and earnings than Prenetics Global. Prenetics Global is trading at a lower price-to-earnings ratio than Medifast, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prenetics Global	$92.39M	3.90	-$37.71M	-$4.16	N/A
Medifast	$385.79M	0.34	-$18.67M	-$2.33	N/A

Prenetics Global has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, Medifast has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market.

25.0% of Prenetics Global shares are owned by institutional investors. Comparatively, 95.5% of Medifast shares are owned by institutional investors. 7.8% of Prenetics Global shares are owned by company insiders. Comparatively, 3.7% of Medifast shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Prenetics Global presently has a consensus target price of $35.67, indicating a potential upside of 66.87%. Medifast has a consensus target price of $12.00, indicating a potential upside of 3.23%. Given Prenetics Global's stronger consensus rating and higher possible upside, equities research analysts plainly believe Prenetics Global is more favorable than Medifast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prenetics Global	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Medifast	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Medifast had 6 more articles in the media than Prenetics Global. MarketBeat recorded 7 mentions for Medifast and 1 mentions for Prenetics Global. Medifast's average media sentiment score of 0.21 beat Prenetics Global's score of -0.09 indicating that Medifast is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prenetics Global	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medifast	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Medifast has a net margin of -8.08% compared to Prenetics Global's net margin of -47.43%. Medifast's return on equity of -6.69% beat Prenetics Global's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prenetics Global	-47.43%	-21.41%	-15.56%
Medifast	-8.08%	-6.69%	-5.25%

Summary

Medifast beats Prenetics Global on 11 of the 16 factors compared between the two stocks.

How does Medifast compare to USANA Health Sciences?

USANA Health Sciences (NYSE:USNA) and Medifast (NYSE:MED) are both small-cap consumer staples companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Medifast had 6 more articles in the media than USANA Health Sciences. MarketBeat recorded 7 mentions for Medifast and 1 mentions for USANA Health Sciences. Medifast's average media sentiment score of 0.21 beat USANA Health Sciences' score of 0.00 indicating that Medifast is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
USANA Health Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medifast	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

USANA Health Sciences has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Medifast has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

USANA Health Sciences has higher revenue and earnings than Medifast. USANA Health Sciences is trading at a lower price-to-earnings ratio than Medifast, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
USANA Health Sciences	$925.26M	0.29	$10.76M	-$1.21	N/A
Medifast	$385.79M	0.34	-$18.67M	-$2.33	N/A

USANA Health Sciences has a net margin of -2.43% compared to Medifast's net margin of -8.08%. USANA Health Sciences' return on equity of 3.41% beat Medifast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
USANA Health Sciences	-2.43%	3.41%	2.50%
Medifast	-8.08%	-6.69%	-5.25%

Medifast has a consensus target price of $12.00, suggesting a potential upside of 3.23%. Given Medifast's stronger consensus rating and higher probable upside, analysts clearly believe Medifast is more favorable than USANA Health Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
USANA Health Sciences	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Medifast	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

54.3% of USANA Health Sciences shares are owned by institutional investors. Comparatively, 95.5% of Medifast shares are owned by institutional investors. 0.8% of USANA Health Sciences shares are owned by company insiders. Comparatively, 3.7% of Medifast shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Medifast beats USANA Health Sciences on 8 of the 14 factors compared between the two stocks.

How does Medifast compare to Niagen Bioscience?

Niagen Bioscience (NASDAQ:NAGE) and Medifast (NYSE:MED) are both small-cap consumer staples companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

Niagen Bioscience presently has a consensus target price of $10.33, indicating a potential upside of 290.67%. Medifast has a consensus target price of $12.00, indicating a potential upside of 3.23%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Niagen Bioscience is more favorable than Medifast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Medifast	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Niagen Bioscience has a net margin of 12.39% compared to Medifast's net margin of -8.08%. Niagen Bioscience's return on equity of 17.95% beat Medifast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	12.39%	17.95%	13.17%
Medifast	-8.08%	-6.69%	-5.25%

15.4% of Niagen Bioscience shares are held by institutional investors. Comparatively, 95.5% of Medifast shares are held by institutional investors. 10.0% of Niagen Bioscience shares are held by company insiders. Comparatively, 3.7% of Medifast shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Medifast had 1 more articles in the media than Niagen Bioscience. MarketBeat recorded 7 mentions for Medifast and 6 mentions for Niagen Bioscience. Medifast's average media sentiment score of 0.21 beat Niagen Bioscience's score of 0.00 indicating that Medifast is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Niagen Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medifast	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Niagen Bioscience has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market. Comparatively, Medifast has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

Niagen Bioscience has higher earnings, but lower revenue than Medifast. Medifast is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42M	1.63	$17.38M	$0.18	14.69
Medifast	$385.79M	0.34	-$18.67M	-$2.33	N/A

Summary

Niagen Bioscience beats Medifast on 13 of the 17 factors compared between the two stocks.

Get Medifast News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MED vs. The Competition

Export

Metric	Medifast	Personal Care Products Industry	Consumer Staples Sector	NYSE Exchange
Market Cap	$130.02M	$22.33B	$15.24B	$22.71B
Dividend Yield	N/A	5.31%	3.32%	3.74%
P/E Ratio	-4.99	20.76	13.86	27.87
Price / Sales	0.34	12.31	263,620.99	20.35
Price / Cash	27.75	27.18	56.97	39.56
Price / Book	0.64	2.80	4.14	4.65
Net Income	-$18.67M	$1.13B	$839.86M	$1.08B
7 Day Performance	-5.14%	-2.56%	-1.92%	-0.76%
1 Month Performance	-8.19%	-7.08%	-5.22%	-4.75%
1 Year Performance	-14.93%	-23.34%	7.93%	6.01%

Medifast Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MED Medifast	1.606 of 5 stars	$11.65 +1.9%	$12.00 +3.0%	-15.7%	$130.19M	$385.79M	N/A	380	Insider Trade
LW Lamb Weston	4.3127 of 5 stars	$43.58 -1.8%	$53.36 +22.4%	-33.7%	$5.99B	$6.61B	20.95	10,000	News Coverage Upcoming Earnings Analyst Forecast
NOMD Nomad Foods	4.9707 of 5 stars	$10.63 -0.4%	$13.25 +24.7%	-19.2%	$1.49B	$2.96B	10.42	7,752	Analyst Forecast Gap Up
PRE Prenetics Global	4.3577 of 5 stars	$22.97 +0.2%	$35.67 +55.3%	+50.3%	$387.60M	$92.39M	N/A	98
USNA USANA Health Sciences	1.1775 of 5 stars	$14.58 +2.2%	N/A	-47.5%	$267.92M	$913.36M	N/A	1,570

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:MED) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medifast (MED) Competitors

MED vs. LW, NOMD, PRE, USNA, and NAGE

How does Medifast compare to Lamb Weston?

Summary

How does Medifast compare to Nomad Foods?

Summary

How does Medifast compare to Prenetics Global?

Summary

How does Medifast compare to USANA Health Sciences?

Summary

How does Medifast compare to Niagen Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MED vs. The Competition

Medifast Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medifast (MED) Competitors

MED vs. LW, NOMD, PRE, USNA, and NAGE

How does Medifast compare to Lamb Weston?

Which has more risk and volatility, MED or LW?

Which has stronger valuation and earnings, MED or LW?

Do insiders & institutionals have more ownership in MED or LW?

Does the media refer more to MED or LW?

Do analysts prefer MED or LW?

Is MED or LW more profitable?

Summary

How does Medifast compare to Nomad Foods?

Does the media prefer NOMD or MED?

Which has better earnings and valuation, NOMD or MED?

Which has more risk and volatility, NOMD or MED?

Is NOMD or MED more profitable?

Do analysts recommend NOMD or MED?

Do insiders and institutionals have more ownership in NOMD or MED?

Summary

How does Medifast compare to Prenetics Global?

Which has stronger valuation & earnings, PRE or MED?

Which has more volatility & risk, PRE or MED?

Do institutionals & insiders believe in PRE or MED?

Do analysts rate PRE or MED?

Does the media prefer PRE or MED?

Is PRE or MED more profitable?

Summary

How does Medifast compare to USANA Health Sciences?

Does the media prefer USNA or MED?

Which has more risk and volatility, USNA or MED?

Which has preferable valuation and earnings, USNA or MED?

Is USNA or MED more profitable?

Do analysts recommend USNA or MED?

Do institutionals and insiders have more ownership in USNA or MED?

Summary

How does Medifast compare to Niagen Bioscience?

Do analysts recommend NAGE or MED?

Is NAGE or MED more profitable?

Do insiders & institutionals hold more shares of NAGE or MED?

Does the media prefer NAGE or MED?

Which has more risk & volatility, NAGE or MED?

Which has stronger earnings and valuation, NAGE or MED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MED vs. The Competition

Medifast Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools